Edition:
United Kingdom

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

20.25USD
8 Dec 2017
Change (% chg)

$-0.15 (-0.74%)
Prev Close
$20.40
Open
$20.40
Day's High
$20.60
Day's Low
$20.05
Volume
142,556
Avg. Vol
223,757
52-wk High
$22.25
52-wk Low
$6.00

Select another date:

Fri, Dec 1 2017

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

BRIEF-Novocure reports qtrly ‍loss per share $0.13​

* Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​ Source text for Eikon: Further company coverage:

BRIEF-Novocure qtrly net revenues $38.4 mln

* Novocure Ltd - ‍for three months ended June 30, 2017, net revenues increased to $38.4 million compared to $17.9 million for same period in 2016​

BRIEF-Novocure to initiate early-stage trial testing its glioblastoma combo therapy

* Novocure™ announces a phase 1b clinical trial to evaluate the safety of marizomib and temozolomide in combination with optune® as adjuvant therapy in patients with glioblastoma

Select another date: